National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma
The heterogeneity of (very) early to intermediate-stage HCC patients and the increasing number of available treatment options means clinical decision-making, including treatment selection, is becoming more complex and diverse. More data are required to define the role of SABR and systemic therapies in very early to intermediate stage HCC before being adopted as standard of care in Australia.
Authors
- Stuart Keith Roberts (ORCID: https://orcid.org/0000-0002-9015-7997)
- John K. Olynyk (ORCID: https://orcid.org/0000-0003-0417-3411)
- Nicholas Shackel (ORCID: https://orcid.org/0000-0002-1751-1400)
- Ammar Majeed (ORCID: https://orcid.org/0000-0002-7024-8787)
- Alan J. Wigg (ORCID: https://orcid.org/0000-0001-8054-5745)
- Simone Irene Strasser (ORCID: https://orcid.org/0000-0001-6374-1525)
- Marnie J. Wood
- Kiran Rasaratnam
Institutions
- Curtin University (AU)
- Royal Brisbane and Women's Hospital (AU)
- Launceston General Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Women's and Children's Health Network (AU)
- Alfred Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1002/cam4.70722
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- AstraZeneca Australia